Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted radionuclide therapy for solid tumors: an overview.

Sally J DeNardo1, Gerald L Denardo

  • 1Radiodiagnosis and Therapy, Division of Hematology/Oncology, University of California Davis Medical Center, Sacramento, CA, USA. sjdenardo@mcdavis.edu

International Journal of Radiation Oncology, Biology, Physics
|September 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In-vivo biodistribution and safety of 99mTc-LLP2A-HYNIC in canine non-Hodgkin lymphoma.

PloS one·2012
Same author

Concepts, consequences, and implications of theranosis.

Seminars in nuclear medicine·2012
Same author

A general chemical synthesis platform for crosslinking multivalent single chain variable fragments.

Organic & biomolecular chemistry·2011
Same author

Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT).

Cancer biotherapy & radiopharmaceuticals·2010
Same author

Halogenated benzimidazole carboxamides target integrin alpha4beta1 on T-cell and B-cell lymphomas.

Cancer research·2010
Same author

The remarkable stability of chimeric, sialic acid-derived alpha/delta-peptides in human blood plasma.

Chemical biology & drug design·2010
Same journal

Single Percussive Ventilation Breath-hold Imaging and Delivery in Lung Tumor Stereotactic Ablative Radiation Therapy: Initial Observations From a Prospective Clinical Trial.

International journal of radiation oncology, biology, physics·2026
Same journal

Proton beam therapy in nonmetastatic rhabdomyosarcoma: Outcome, prognostic factors and the effect of timing of radiation therapy.

International journal of radiation oncology, biology, physics·2026
Same journal

Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series.

International journal of radiation oncology, biology, physics·2026
Same journal

Gastrointestinal Motility-Induced Interplay in Pancreas Proton Therapy: Motion Simulation and Dosimetric Impact.

International journal of radiation oncology, biology, physics·2026
Same journal

Intra-fractional Voxel-wise Anatomical Motion Tracking Guided by Multimodal Respiratory Surrogates in Radiotherapy: Framework Development and Multi-Center Validation.

International journal of radiation oncology, biology, physics·2026
Same journal

A Gaussian-based planning approach for robust dose-escalated stereotactic body proton therapy.

International journal of radiation oncology, biology, physics·2026
See all related articles

Radioimmunotherapy (RIT) shows promise for solid tumors when combined with other treatments. Strategic sequencing and novel delivery methods, like nanoparticles, enhance RIT efficacy and minimize toxicity for better therapeutic outcomes.

Area of Science:

  • Oncology
  • Radiology
  • Nanotechnology

Background:

  • Radioimmunotherapy (RIT) is effective for non-Hodgkin's lymphoma (NHL) but shows limited efficacy as a standalone treatment for solid tumors.
  • Improving the therapeutic index (TI) and integrating RIT into combined modality therapy (CMRIT) are crucial for solid tumor treatment.
  • Preclinical and clinical data highlight the potential of synergistic CMRIT strategies.

Purpose of the Study:

  • To explore the potential of combined modality radioimmunotherapy (CMRIT) for treating solid tumors.
  • To investigate novel approaches for enhancing RIT efficacy, including vascular targeting and nanoparticle delivery.
  • To emphasize the importance of optimal sequencing and timing in CMRIT protocols.

Main Methods:

  • Review of preclinical and clinical studies on RIT and CMRIT for solid tumors.

Related Experiment Videos

  • Exploration of synergistic combinations, including nanoparticles and alternating magnetic frequency (AMF) therapy.
  • Utilizing radionuclide imaging (e.g., PET) for quantitative assessment of treatment effects.

    • Main Results:

    • Evidence suggests that appropriate combination and sequencing of RIT in CMRIT can lead to effective solid tumor treatment.
    • Vascular targets and nanoparticles offer opportunities to enhance RIT, potentially combined with drug delivery or thermal ablation.
    • Quantitative imaging can effectively monitor the impact of CMRIT sequence and timing.

    Conclusions:

    • CMRIT, with strategic sequencing and novel delivery systems, holds significant potential for treating solid tumors.
    • Optimizing the interplay between RIT and other modalities is key to maximizing therapeutic benefit while minimizing toxicity.
    • Quantitative imaging provides a valuable tool for clinical assessment and refinement of CMRIT strategies.